Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 4/20 | 0.48 |
| ▸ | GRIN3B | O60391 | 4/20 | 0.48 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.48 |
| ▸ | GRIN2A | Q12879 | 4/20 | 0.48 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.48 |
| ▸ | GRIN2C | Q14957 | 4/20 | 0.48 |
| ▸ | GRIN3A | Q8TCU5 | 4/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.31 |
| ▸ | GBA1 | P04062 | 2/20 | 0.30 |
| ▸ | GBA2 | Q9HCG7 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5251164 | 0.90 | GRIN2D (0.61) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL8413718 | 0.88 | GRIN2D (0.59) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL58465 | 0.88 | GRIN2D (0.59) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL891670 | 0.82 | GRIN2D (0.60) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL10957944 | 0.75 | GRIN2D (0.76) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL8626986 | 0.74 | GRIN2D (0.48) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL891808 | 0.73 | GRIN2D (0.35) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL21357299 | 0.72 | GRIN2D (0.78) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL2757 | 0.70 | GRIN2D (0.56) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL24728057 | 0.67 | GRIN2D (0.64) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240197888-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | 2024-06-20 | — | — | US | claimed |
| WO-2023150601-A2 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2023-08-10 | — | — | WO | claimed |
| WO-2021069671-A1 | HEXAHYDRO-5,8-EPOXYCYCLOHEPTA[c]PYRAZOLE DERIVATIVES USEFUL AS MODULATORS OF THE CB1 AND/OR CB2 RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-04-15 | — | — | WO | claimed |
| US-20210070769-A1 | SUBSTITUTED AZETIDINE DIHYDROTHIENOPYRIMIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | UNION therapeutics A/S (DK) | 2021-03-11 | — | — | US | claimed |
| EP-1408034-B2 | Use of Quinolone and Quinolizinone derivatives as chemotherapeutic agents | BAYER INNOVATION GMBH (DE) | 2011-05-25 | — | — | EP | claimed |
| US-5605910-A | BACTERICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1997-02-25 | — | — | US | claimed |
| EP-0721948-A1 | Quinolone- and naphthyridone carboxylic acid derivatives as antibacterial agents | BAYER AG (DE) | 1996-07-17 | — | — | EP | claimed |
| US-20240197888-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | 2024-06-20 | — | — | US | disclosed |
| US-20240109910-A1 | HEXAHYDRO-5,8-EPOXYCYCLOHEPTA[c]PYRAZOLE DERIVATIVES USEFUL AS MODULATORS OF THE CB1 AND / OR CB2 RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-04-04 | — | — | US | disclosed |
| WO-2023150601-A2 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2023-08-10 | — | — | WO | disclosed |
| US-20230137932-A1 | CYANO-PYRIMIDINE INHIBITORS OF EGFR/HER2 | DANA-FARBER CANCER INSTITUTE, INC. | 2023-05-04 | — | — | US | disclosed |
| EP-3512849-B1 | 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDIN-3-CARBOXAMIDES AND THEIR USE | BAYER AG (DE) | 2021-06-23 | — | — | EP | disclosed |
| WO-2021069671-A1 | HEXAHYDRO-5,8-EPOXYCYCLOHEPTA[c]PYRAZOLE DERIVATIVES USEFUL AS MODULATORS OF THE CB1 AND/OR CB2 RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-04-15 | — | — | WO | disclosed |
| EP-2118111-A1 | 2-AMIN0-5, 7-DIHYDR0-6H- PYRROLO [3, 4-D] PYRIMIDINE DERIVATIVES AS HSP-90 INHIBITORS FOR TREATING CANCER | Pfizer Inc. (US) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008096218-A1 | 2-AMIN0-5, 7-DIHYDR0-6H- PYRROLO [3, 4-D] PYRIMIDINE DERIVATIVES AS HSP-90 INHIBITORS FOR TREATING CANCER | PFIZER INC. (US) | 2008-08-14 | — | — | WO | disclosed |
| EP-0704443-B1 | Quinolone and naphthyridone carboxylic acid derivatives | BAYER AG (DE) | 2000-12-27 | — | — | EP | disclosed |
| US-5990122-A | SUBSTITUTED IN THE 7-POSITION BY A TRICYCLIC AMINE RADICAL; REDUCED GENOTOXIC PROPERTIES AND INCREASED ANTIBACTERIAL ACTIVITY | BAYER AKTIENGESELLSCHAFT (DE) | 1999-11-23 | — | — | US | disclosed |
| US-5986105-A | ENANTIOMORPHS AS BACTERICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1999-11-16 | — | — | US | disclosed |
| US-5605910-A | BACTERICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1997-02-25 | — | — | US | disclosed |
| EP-0704443-A2 | Quinolone and naphthyridone carboxylic acid derivatives | BAYER AG (DE) | 1996-04-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240197888-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | SOS1, SOS2, SOST | GRIN2D 4865/4885GRIN3B 4813/4885GRIN1 4093/4885 |
| US-20230137932-A1 | CYANO-PYRIMIDINE INHIBITORS OF EGFR/HER2 | ERBB2, EGFR, ERBB3 | GRIN2D 3283/4885GRIN3B 3143/4885GRIN1 3521/4885 |
| US-20210070769-A1 | SUBSTITUTED AZETIDINE DIHYDROTHIENOPYRIMIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | PDE2A, PDE5A, PDE3A | GRIN2D 4118/4885GRIN3B 3830/4885GRIN1 4160/4885 |
| US-20240109910-A1 | HEXAHYDRO-5,8-EPOXYCYCLOHEPTA[c]PYRAZOLE DERIVATIVES USEFUL AS MODULATORS OF THE CB1 AND / OR CB2 RECEPTORS | CNR2, CNR1, GPR55 | GRIN2D 964/4885GRIN3B 748/4885GRIN1 1016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.